TFF Pharmaceuticals Collaborates with Emory University and BARDA to Develop Dry Powder-Based mRNA Treatment for Influenza and COVID Page 1

Partnership funded by BARDA and other U.S. government agencies

The TFF formulation can provide supply flexibility and improve storage and distribution conditions

FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative medicines based on its proprietary Thin Film Freezing (TFF) technology platform, today announced its new partnership with Emory University and the Biomedical Advanced Research and Development Authority (BARDA). Under the partnership, TFF Pharmaceuticals will test the feasibility of converting Emory’s mRNA-based Cas13a antiviral against influenza A and B and SARS-CoV-2 into a dry powder formulation for more precise inhalation administration, improved stability, and widespread distribution without the need for cold chain storage.